However, as the most common treatment for NSCLC, chemo can induce systemic immunosuppression, thus inhibiting the differentiation and maturation of CD3+ and CD4+ T lymphocytes, resulting in the decrease of CD3+ and CD4+ T lymphocytes and NK, as well as the imbalance between CD4+ and CD8+ [30, 31]. This evidence concerns the gene CD8A and non-small cell lung carcinoma.